Actinium's Antibody Radiation Conjugates and Novel Linker Tech to be Presented at 2024 SNMMI Meeting
Actinium Pharmaceuticals, Inc., a frontrunner in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, has announced the acceptance of five abstracts for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting. The event is scheduled to be held from June 8 to June 11, 2024, in Toronto, Canada.
The abstracts will spotlight key findings from the Phase 3 SIERRA trial of Iomab-B, which targets CD45 with an Iodine-131 payload. This therapeutic is designed for conditioning patients to prepare them for potentially life-saving bone marrow transplants (BMT). Additionally, results will be presented from a Phase 1b trial of Actimab-A, which targets CD33 with an Actinium-225 payload, in conjunction with the chemotherapy regimen CLAG-M. Both Iomab-B and Actimab-A are unique in their development as the only targeted radiotherapies for patients with relapsed or refractory acute myeloid leukemia (r/r AML), a type of blood cancer highly responsive to radiation. An abstract introducing proprietary linker technology for solid tumor targeting ARCs will also be presented for the first time.
Sandesh Seth, Chairman and CEO of Actinium, emphasized the company's leadership and broad capabilities in developing Antibody Radiation Conjugates. He expressed enthusiasm about showcasing the potential of targeted radiotherapy in treating blood cancers to the nuclear medicine community, which he sees as a significant growth opportunity for the field. The SNMMI presentations will underscore the potential of Iomab-B and Actimab-A to treat high-risk, difficult-to-treat r/r AML, including overcoming mutations like TP53 and addressing patients with extensive prior therapies.
Actinium's presentations at the SNMMI Annual Meeting will include:
1. Safety and Dosimetric Analysis of Lintuzumab-Ac225 in Combination with Intensive CLAG-M Chemotherapy in Patients with Relapsed/Refractory AML
2. Exploratory Analysis of Bone Marrow Dosimetry from the Randomized Phase 3 SIERRA Trial of Iomab-B (131I-apamistamab) Prior to HCT in Relapsed/Refractory Acute Myeloid Leukemia
3. Survival Outcomes and Dosimetric Analysis of Iomab-B (131I-apamistamab) Followed by Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated Relapsed/Refractory AML
4. Mathematical Modeling of Exposure Measurements Following High-Dose Targeted Therapy Using 131I-apamistamab: Analysis From the Large Multicenter Phase III SIERRA Trial
5. Evaluation of Novel DOTA-based Linkers for Improved Targeted Radiotherapy Delivery to Solid Tumors
The SNMMI Annual Meeting is renowned as a premier event for education, scientific exchange, research, and networking in the field of nuclear medicine and molecular imaging. The four-day event in June offers an in-depth view of the latest research and development, providing insights into practical applications for clinical settings.
Actinium Pharmaceuticals focuses on developing targeted radiotherapies to significantly improve survival rates for patients who have not responded to existing oncology treatments. The company’s advanced pipeline includes Iomab-B, which is being prepared for regulatory submission as a bone marrow transplant conditioning agent, and Actimab-A, which is on a pivotal development path in collaboration with the National Cancer Institute. Both therapies have demonstrated potential to extend survival outcomes for patients with relapsed and refractory acute myeloid leukemia. Actinium plans to expand the application of Iomab-B to other blood cancers and is advancing Iomab-ACT to improve outcomes for cell and gene therapy. The company holds over 230 patents and patent applications, including several related to the cyclotron production of the isotope Ac-225.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
